Alzheimer’s Disease Trial Designs Struggle To Turn Noise Into Sound

Infographic compares pivotal trials for Alzheimer's disease-modifying candidates from Biogen/Eisai, Lilly and Roche.

brain scan
• Source: Shutterstock

Two amyloid-targeting Alzheimer’s disease therapies had Phase III trials read out in the last month, with divergent results that reflect the risk-strewn landscape for sponsors trying to study the neurodegenerative disease: Roche Holding AG pulled the plug on its early AD program for gantenerumab for lack of efficacy in the GRADUATE program, while Biogen, Inc. and Eisai Co., Ltd. won plaudits for lecanemab’s showing in the CLARITY AD trial as best evidence yet of a disease-modifying effect.

The high level of unmet need in Alzheimer’s disease contributed to the FDA's decision to award accelerated approval to Biogen's...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Clinical Trials

More from R&D

  • India Tightens Oversight Of CROs With Mandatory Registration

     
    • By 

    Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

  • Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

     
    • By 

    The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

  • How To Decarbonize Pharma R&D

     

    As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.